Mineralys Therapeutics (MLYS) is preparing to launch lorundrostat (December 22 PDUFA), a second-to-market aldosterone synthase inhibitor, or ASI, with limited clear differentiation from BAXFENDY (baxdrostat) on efficacy or safety (per my
CryptoAlerta — análise de criptomoedas e mercado em tempo real